8-K: Verve Therapeutics Reports Positive Phase 1b Data for VERVE-102 and Provides Financial Update

Verve Therapeutics announces positive initial data from its Heart-2 Phase 1b clinical trial of VERVE-102, demonstrating dose-dependent LDL-C reductions, and reports a cash runway into mid-2027.

Summary

• Verve Therapeutics reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, showing dose-dependent decreases in LDL-C and PCSK9.
• A single infusion of VERVE-102 in the 0.6 mg/kg dose cohort resulted in a mean LDL-C reduction of 53%, with a maximum reduction of 69%.
• The Pulse-1 Phase 1b clinical trial of VERVE-201, targeting ANGPTL3, is progressing, with an update expected in the second half of 2025.
• Verve's cash, cash equivalents, and marketable securities totaled approximately $500 million, providing a cash runway into mid-2027.
• The company expects to dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025.
• Collaboration revenue for the first quarter of 2025 was $33.0 million, compared to $5.7 million for the first quarter of 2024.
• Net loss for the first quarter of 2025 was $31.0 million, or $0.35 per share, compared to $48.7 million, or $0.59 per share, for the first quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical data, a strong cash position, and strategic collaborations, indicating a favorable outlook for Verve Therapeutics. The company is making progress in its clinical trials and has a clear path forward.

Positives

• VERVE-102 shows promising dose-dependent reductions in LDL-C and PCSK9.
• The company has a strong cash position, providing a runway into mid-2027.
• The FDA granted Fast Track designation to VERVE-102.
• Collaboration revenue increased significantly due to the Vertex Pharmaceuticals collaboration termination and progress with the Lilly collaboration.
• Net loss per share decreased compared to the same quarter in the previous year.

Negatives

• The company reported a net loss of $31.0 million for the first quarter of 2025.
• Research and development expenses increased compared to the first quarter of 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including regulatory approvals, clinical trial outcomes, and the ability to raise additional capital.
• There are risks associated with the company's limited operating history.
• The company needs to manage expenses and raise substantial additional capital to achieve its business objectives.

Future Outlook

Verve expects to dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025 and provide further updates, including final data from the Heart-2 trial and a decision from Eli Lilly on the PCSK9 program, also in the second half of 2025. The company anticipates its cash position will be sufficient to fund operations into mid-2027.

Management Comments

• Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics, stated that 2025 is off to a strong start with both clinical and regulatory progress.
• Dr. Kathiresan believes VERVE-102 can become a highly competitive option compared to existing therapies for cardiovascular disease.
• Dr. Kathiresan mentioned that the company is well-positioned to achieve its goals with cash runway into mid-2027.

Industry Context

Verve Therapeutics is developing genetic medicines for cardiovascular disease, targeting key lipoprotein drivers of atherosclerosis like LDL-C, triglycerides, and Lp(a). The company's approach of single-course gene editing medicines aims to transform treatment from chronic therapies to a one-time intervention, potentially disrupting the market for existing lipid-lowering drugs.

Comparison to Industry Standards

• The reported 53% mean reduction in LDL-C with VERVE-102 is competitive with existing PCSK9 inhibitors like Amgen's Repatha and Sanofi/Regeneron's Praluent, which typically demonstrate LDL-C reductions of around 50-60%.
• Unlike current PCSK9 inhibitors that require chronic administration, VERVE-102 aims for a single-course treatment, which could offer a significant advantage in patient compliance and long-term efficacy.
• The development of VERVE-201 targeting ANGPTL3 aligns with industry interest in this target, as evidenced by Regeneron's evinacumab, an ANGPTL3 inhibitor approved for homozygous familial hypercholesterolemia.
• Verve's approach to Lp(a) reduction with VERVE-301 addresses a significant unmet need, as current therapies have limited impact on Lp(a) levels; Amgen, Novartis, and other companies are also developing Lp(a)-lowering therapies, indicating the importance of this target.

Stakeholder Impact

• Shareholders may benefit from the positive clinical data and strong financial position.
• Patients with cardiovascular disease may have access to new and potentially transformative treatments.
• Employees are likely to be impacted by the company's continued growth and development.

Next Steps

• Dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025.
• Announce final data from the dose escalation portion of the Heart-2 clinical trial in the second half of 2025.
• Deliver the opt-in package for the PCSK9 program to Eli Lilly and Company in the second half of 2025.
• Receive a decision from Lilly on the PCSK9 program in the second half of 2025.
• Provide a program update on VERVE-201 in the second half of 2025.
• Continue preclinical studies for VERVE-301.

Key Dates

Keywords

VERVE-102, VERVE-201, VERVE-301, LDL-C, PCSK9, ANGPTL3, Lp(a), Hypercholesterolemia, Cardiovascular Disease, Gene Editing, Clinical Trial, Financial Results